Clinical trials targeting CD19 on B-cell malignancies are underway with encouraging anti-tumor responses. Most infuse T cells genetically modified to express a chimeric antigen receptor (CAR) with specificity derived from the scFv region of a CD19-specific mouse monoclonal antibody (mAb, clone FMC63). We describe a novel anti-idiotype monoclonal antibody (mAb) to detect CD19-specific CAR + T cells before and after their adoptive transfer. This mouse mAb was generated by immunizing with a cellular vaccine expressing the antigen-recognition domain of FMC63. The specificity of the mAb (clone no. 136.20.1) was confined to the scFv region of the CAR as validated by inhibiting CAR-dependent lysis of CD19 + tumor targets. This clone can be used to detect CD19-specific CAR + T cells in peripheral blood mononuclear cells at a sensitivity of 1:1,000. In clinical settings the mAb is used to inform on the immunophenotype and persistence of administered CD19-specific T cells. Thus, our CD19-specific CAR mAb (clone no. 136.20.1) will be useful to investigators implementing CD19-specific CAR + T cells to treat B-lineage malignancies. The methodology described to develop a CAR-specific anti-idiotypic mAb could be extended to other gene therapy trials targeting different tumor associated antigens in the context of CARbased adoptive T-cell therapy.
Introduction
Genetically modified T cells engineered to express a tumorspecific chimeric antigen receptor (CAR) have been infused initially with modest [1, 2, 3] and recently significant anti-tumor effects [4, 5, 6, 7, 8] . The prototypical CAR uses an extracellular domain to directly dock to a cell surface molecule which is usually a tumor-associated antigen (TAA). The specificity of a CAR is typically derived from a scFv region assembled from the antigenbinding region of a TAA-specific monoclonal antibody (mAb). The components of the 2 nd generation CD19-specific CAR currently used in our clinical trials (Clinical trial.gov Id# NCT00968760, NCT01497184, NCT01362452), designated CD19RCD28 are shown in Fig. 1A . The scFv from mouse mAb clone FMC63 [9] is fused in frame to an extracellular scaffold (e.g., human immunoglobulin hinge and Fc regions or hinge and constant regions from human CD8a) to promote oligomerization after binding TAA which contributes to CAR-dependent activation via one or more signaling motifs in the endodomain. Multiple Phase I clinical trials designed to treat B-cell malignancies redirect the specificity of CAR + T cells based on the CD19-specific mAb clone FMC63 [9, 10] .
Investigators measure the persistence of adoptively transferred T cells in vivo to assess the therapeutic potential of CAR + T cells [5, 11] . The most common approach to assessing survival of infused CAR + T cells is quantitative PCR using CAR-specific primers [4, 12] . However, this technique does not allow retrieval of genetically modified T cells from the recipient for multi-parameter analyses. What is needed and is provided here is a mAb to specifically detect and isolate CD19-specific CAR + genetically modified T cells. In addition to informing on persistence, a CARspecific mAb can be used for in-process testing during manufacture to assess expression of the transgene, such as after electrotransfer of Sleeping Beauty (SB) or piggyBac DNA plasmids coding for CD19RCD28 [13, 14, 15, 16] .
We report here an approach for developing an anti-idiotype (anti-Id) mAb with specificity for CD19-specific CARs that could be extended to other CARs targeting alternative TAAs. The mouse mAb (clone no. 136.20.1) characterized in this paper recognizes CD19-specific CARs derived from anti-human CD19 mAb (clone FMC63). We show specificity of this mAb for CD19-specific CAR using (i) flow cytometry, (ii) western blotting, (iii) transmission electron microscopy (TEM), and (iv) immunocytochemistry. The binding of this anti-Id to the scFv region of CD19RCD28 was demonstrated using a panel of CAR + T cells and inhibition of CD19-dependent cytolysis as observed by chromium release assay (CRA) and video time lapse microscopy (VTLM). The scFv is derived from mAb clone FMC63 that binds human CD19 and was generated by fusing the V L and V H regions via a ''Whitlow'' linker peptide. The scFv was attached to modified human IgG 4 hinge and CH 2 -CH 3 regions that was fused to the CD28 (transmembrane and cytoplasmic) and CD3f (cytoplasmic) domains [24] (B) DNA plasmid design CD19scFv-mCD8a used to express the transgene on L cells for immunization and screening. The CD19-specific scFv was generated as described above, mCD8a EC and TM represents mouse CD8a extracellular and transmembrane domains respectively. (C) Map of destination vector pIRESneo2 (Clontech) where the cDNA for the fusion protein CD19scFv-mCD8a is cloned into NheI and NotI restriction enzyme sites. Expression cassette shows ColE1, colicin E1 (origin of replication); pCMV IE, human cytomegalovirus promoter/enhancer; ECMV IRES, encephalomyocarditis virus internal ribosome entry site which permits translation of two open reading frames from one messenger RNA, and poly A (polyadenylation) signal of the bovine growth hormone. Plasmid confers resistance through ampicillin and after electroporation the cells expressing the transgene of interest are selected on cytocidal concentration of drug neomycin sulfate (G418 
Materials and Methods

Ethics Statement
All experimental procedures pertaining to the use of animals were performed according to the U.T. MD Anderson Cancer Center Institutional Animal Care and Use Committee (IACUC) guidelines and were carried out by the MD Anderson Hybridoma core lab (IACUC approval no. 11-071-2533). All efforts were made to reduce suffering to the animals caused by any experimental procedure. Isoflurane (2-5%) were used as anesthesia whenever required. Details of animal care, anesthesia use and sample collection are provided in separate paragraph. For the peripheral blood mononuclear cells (PBMC) used in the study, blood samples were obtained from healthy volunteers under the protocol title ''Acquisition of peripheral blood from healthy volunteers'' that aimed to investigate the immunobiology of lymphocytes such as T cells in general and genetically modified T cells in particular (approval obtained from U.T. MD Anderson Cancer Center Institutional Review Board protocol no. LAB07-0296). Healthy volunteers donated blood only after written consent was obtained and the study objectives were explained.
Cells
Cell lines were obtained from American Type Culture Collection (ATCC) center unless otherwise stated. L cells, (a mouse adherent fibroblast cell line derived from C3H/An strain; ATCC no. CRL-2648), Jurkat cells (ATCC no. CRL-1990), NSO cells (Sigma Aldrich no. 85110503), NALM-6 pre-B ALL cell (DSMZ no. ACC 128), EL4 murine lymphoma T cell line (ATCC no. TIB-39), CD19
+ EL4 (genetically modified to express truncated human CD19) [17] , Daudi co-expressing EGFP and b 2 -microglobulin (Daudi b 2 m), were all cultured in complete media (CM) defined as RPMI 1640 (Hyclone) supplemented with heat inactivated 10% fetal bovine serum (FBS) (Hyclone) and 2 mM L-Glutamine (Gibco-Invitrogen). Genetically modified cells were selected in various cytocidal concentrations of neomycin sulfate G418 (Invivogen) at 0.8 mg/mL for NSO cells, 0.9 mg/mL for L cells and 1 mg/mL for Jurkat cells [13] . K562 were transduced with lentivirus to co-express CD64, CD86, CD137L and a membrane-bound IL-15 (mIL15) to generate artificial antigen presenting cells (aAPC clone no. 4) [8, 13, 14, 16] . Primary human T cells from PBMC were genetically modified to express CD19RCD28 CAR using the Sleeping Beauty (SB) transposon/ transposase system and propagated ex vivo in a CAR-dependent manner on CD19 + aAPC (K562, clone no. 4) in CM supplemented with soluble recombinant IL-2 (Novartis/Chiron) at 50 IU/ mL and IL-21 at 30 ng/mL (Peprotech) [16, 18] .
Cell Surface xpression of CD19-specific scFvV L (amino terminus) and V H (carboxyl terminus) regions were derived from anti-human CD19-specific mAb clone FMC63 [9] . The scFv was formed by joining the V L and V H with 18 amino acid (AA) Whitlow peptide linker (GSTSGSGKPGSGEGSTKG) [19] . This binding domain denoted as CD19scFv was then fused in frame with mouse CD8a extra-cellular domains (AA and transmembrane domains (AA 197-217) (Swiss-Prot No.P01731 www.expasy.org) to create the fusion protein CD19scFvmCD8a. The cDNA representing the fusion protein was mouse codon optimized and synthesized by a commercial vendor (Fig. 1B,  GENEART) . The nucleotide sequence of CD19scFvmCD8a was verified and the cDNA was cloned into plasmid pIRESneo2 (Clontech cat no. 6938-1) to generate DNA vector CD19scFvmCD8apIRESneo2 (Fig. 1C) Animal Care, Immunization, Lymphocyte Collection
All the experiments pertaining to the animal use were performed as per the recommendations of the U.T. MD Anderson Cancer Center Institutional Animal Care and Use Committee (IACUC approval no. 11-071-2533). Two BALB/c mice (NCI, Frederick) were immunized in the footpads, each with 5610 6 L cells expressing CD19scFv-mCD8a (clone no. 12) suspended in 50 mL PBS. No adjuvant was used for immunization. The mice were restrained manually (for less than 2 minutes) for cell injection or anesthetized by isoflurane (2-5%) whenever required. Each mouse received a total of 6 injections at every 3 days interval. At the end of 5 th immunization, mice were anesthetized by isoflurane (2-5%) inhalation and then blood was drawn from the tail vein. Sera were used to evaluate the antibody titer in an indirect ELISA as described (Supplementary info method S1). On Day 18 a mouse with highest titer was chosen for lymphocyte collection and fusion. Mice were euthanized by CO 2 inhalation and then popliteal lymph nodes were dissected for collection of lymphocytes.
Generation of Hybridomas
A schematic outlining the steps involved for development and isolation of a mAb with specificity for the CD19scFv region in CD19RCD28 CAR is shown in supplementary info Fig. S1 . In brief, lymphocytes were washed with RPMI 1640 and then fused with a myeloma partner SP2/0 (ATCC no. CRL1581) at a lymphocyte to myeloma ratio of 1:0.8. Hybridomas were obtained by standard polyethylene glycol (PEG-1450, SigmaAldrich) mediated fusion technology. Fused cells were grown in 96-well tissue-culture plates for 10 days in HAT selection media (Sigma-Aldrich) supplemented with 10% hybridoma cloning supplement (HCS) (GE/PAA Lab Inc). Hybridoma clones were screened on day 10 to evaluate for the presence of antibody.
Screening Hybridoma Clones
A solid phase ELISA was used to screen for hybridoma clones producing mAb specific for CD19scFv. Details of screening hybridoma clones are provided in Supplementary method S1. Monoclonal antibodies were purified by standard protein G or protein A columns. Details of purification and conjugation procedures are shown in Supplementary method S2. One hybridoma clone (no. 136.20.1) was selected for characterization.
Flow Cytometry
For detecting surface expression of CAR, about 0.25610 6 cells were suspended in 0.1 mL of FACS buffer (2% FBS in 1X PBS) and stained with antibodies conjugated to fluorochromes (Table S1 ). Following blocking for 30 minutes at 4uC with 2% normal mouse sera (Jackson ImmunoResearch) in FACS buffer and washing twice with FACS buffer, the samples were incubated on ice with primary antibodies or conjugated antibodies for 30 minutes. Data were acquired on a FACSCalibur (BD Biosciences) using CellQuest software, version 3.3 (BD Biosciences). Dot plot analyses or MFI (median fluorescence intensity) was calculated by either FCS Express version 3.00.007 (Thornhill) or FlowJo software (version 7.6). To determine the sensitivity of anti-CD19scFv mAb (clone no. 136.20.1), CD19-specific CAR + T cells were mixed with PBMC obtained from healthy donors (CAR neg cells) at varying cell ratios (1:10-1:10,000 CAR + T cell to PBMC). AlexaFluor-647 conjugated mAb (clone no. 136.20.1) was used to detect CAR + T cells by flow cytometry.
Binding Assay
Binding activity of purified anti-CD19scFv mAb (clone no. 136.20.1) was determined by an indirect ELISA. In brief, wells of a 96-well plate (Thermo Scientific Nunc) were coated with 100 ng of following mAbs: anti-human CD19 mAb (clone FMC63, Millipore), anti-human CD19 mAb (clone MHCD1900, Gibco-Invitrogen), anti-human CD20 mAb (clone no. 1F5.1D4.1 derived by us from clone 1F5, clone no. HB-9645, ATCC), human IgG (Jackson ImmunoResearch) in 0.1 mL of coating buffer (100 mM NaHCO 3 pH 8.6). The plates were incubated at 37uC for 1 hour and then washed three times with PBST (1XPBS with 0.05% tween-20). Blocking was achieved with 300 mL of 5% BSA in PBST. A dose curve was generated using different concentrations of purified anti-CD19scFv primary mAbs (2-30 mg/mL) and detected by secondary antibody goat anti-mouse IgG Fc HRP (Sigma-Aldrich). Absorbance was read at 450 nm using a microplate reader (Victor 2030, Perkin Elmer).
Western Blot
Reactivity of anti-CD19ScFv mAb (clone no. 136.20.1) to SDSdenatured protein was tested by western blot analysis. 10 7 CAR modified or unmodified control T cells were lysed using RIPA buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 0.1% SDS, 0.5% Sodium Deoxycholate, 1% TritonX100, 1 mM PMSF) containing protease inhibitor tablet as per manufacturer's instructions (Roche Applied Science). Protein concentration was determined by a BCA kit (Thermo Scientific Pierce). 10 mg of total protein obtained from each cell lysates were electrophoresed under denaturing condition on a 4-20% gradient gel (Biorad) followed by electrobloting onto a PVDF membrane using criterion blotter (Biorad). PVDF membrane was blocked using 5% skim milk in PBST, and then incubated with primary anti-CD19ScFv mAb (clone no. 136.20.1). Binding was detected by goat anti-mouse IgG Fc HRP (SigmaAldrich) enhanced with ECL Westfemto TM substrate (Thermo Scientific Pierce). Images of blots were acquired on a gel doc image system using versa doc Quantityone TM software (Biorad).
Microscopy
For confocal microscopy genetically modified T cells expressing CD19RCD28 CAR were fixed in 4% paraformaldehyde (EMS Inc.) and stained with AlexaFluor 647 conjugated anti-CD19scFv mAb (clone 136.20.1) at 1:500 using standard protocol. Labeled cells were added with ProLong gold anti-fade reagent with DAPI (Gibco-Invitrogen) and viewed under a confocal microscope (Leica Microsystems). Cells were also fixed in neutral buffer formalin for H&E staining and visualization of CAR+ T cells by DAB staining (Details are provided as supplementary method S3). For TEM, CAR + T cells were fixed in 1% glutaraldehyde (Sigma-Aldrich) followed by washing with PBS. The cells were then incubated in 20 mM glycine-PBS followed by washing with PBS-BSA buffer (20 mM phosphate, 150 mM NaCl pH 7.4 containing 0.5% BSA and 0.1% gelatin). NANOGOLD antibody conjugates (Supplementary method S2) were diluted 1:50 in PBS-BSA buffer and incubated with CD19-specific CAR + T cells for 15 min followed by washing with the same buffer to remove unbound conjugates. Finally, NANOGOLD bound cells were fixed with 1% glutaraldehyde and stored in 4uC until further use. Before sectioning cells were subjected to an alcohol dehydration steps (5 to 100% graded alcohol separated in 5 steps) followed by embedding in epoxy resin. The resin embedded cells were then cut into sections (1 mm to 100 nm thickness) in an ultra-microtome (Leica Microsystem). Sections were drawn onto a formavar coated copper grid. Staining was done by 2% uranyl acetate and then air dried. Unstained samples underwent silver enhancement method (Nanoprobes) so that surface bound NANOGOLD particles could be visualized. High magnification images were acquired by a 1 k61 k CCD camera attached to a JEM-1200 EX60KV electron microscope (JEOL).
Chromium Release Assay (CRA)
The functionality of anti-CD19scFv mAb was assessed in a CD19-specific CAR + T cell mediated cytolysis in a standard 4 hour chromium ( 51 Cr) release assay (CRA) employing parental CD19 neg EL4, CD19 + EL4, CD19 + Daudib 2 m and CD19 + NALM-6 as targets [13, 16] . Effector cells (ex vivo expanded CD19RCD28 CAR + T cells harvested on day 28) were incubated with various concentrations of purified mAb (clone 136.20.1) at 10-fold serial dilution (maximum dose at 250 mg/mL and minimum at 1.25 mg/mL) for 20 min at 4uC, followed by washing with RPMI 1640 to remove unbound antibodies. The antibodybound effector cells were incubated with 51 Cr labeled target cells in a clear v-bottom 96-well plate (Corning) at 37uC. Release of 51 Cr was quantified in a micro-plate scintillation counter TopCount NXT (Perkin-Elmer). Specific lysis was calculated for effector to target cell (E:T) ratios in the presence and absence of anti-CD19scFv mAb. Data are reported as mean 6 standard deviation (SD).
Video Time Lapse Microscopy (VTLM)
CD19-specific T cells expressing CD19RCD28 CAR were washed in sterile 16 PBS and stained for 30 min at room temperature using AlexaFluor 647-conjugated to anti-CD19ScFv mAb (clone no. 136.20.1) at 2 mg mAb per 100,000 cells and then washed three times with 16 PBS. The CAR + T cells were mixed together with EGFP + Daudib 2 m at an effector to target ratio of 2:1. A cell pellet was made by brief centrifugation and then resuspended in media RPMI 1640 and put in one of the chamber of a 35 mm culture dish (Nikon). This was kept in the specimen chamber of Biostation IM (Nikon) and allowed to settle for 10 min. CCD camera focal planes were fixed and the effector to target cell dynamics were assessed for 2 to 12 hours using imaging software (IM-Q, v2.1.2.136, Nikon). As control, APC-conjugated goat antihuman IgG Fcc chain specific F(ab9) 2 fragment antibody (Jackson ImmunoResearch) was used to bind CAR + T cells and the coculture was set up as described. 
Results
Generating Anti-ScFv mAb Recognizing CD19RCD28 CAR
We immunized BALB/c mice using L cells (derived from C3H/ An mouse strain) genetically modified to express the scFv region in a CD19-specific CAR (Fig. S1 ). The scFv was derived from FMC63 (encoded in DNA plasmid CD19scFv-mCD8a) and stably expressed (.90% homogenous expression after single-cell sorting) on the surface of neomycin-resistant genetically modified L cells which was used to immunize allogeneic mice. The murine CD8a trans-membrane and extra-cellular region was used to display scFv on surface and to detect expression (Fig. 1B and 1C) . Genetically modified L cells were injected in mice at 3 day interval and high titer sera (OD values ,5 times above background at 1:2,700 dilution) was obtained after five successive immunizations. Hybridomas were generated and ELISA was used to initially select 23 ''high binders'' (OD 450 .1.5) and 15 ''moderate binders'' (OD 450 ,1.00-1.5) to advance to the second round of screening. Flow cytometry using Jurkat and NSO cells genetically modified with CD19scFv-mCD8a was used to cull the number of candidate hybridomas to 12. The specificity of mAb (clone no. 136.20.1) towards CD19scFv was initially evaluated by an indirect ELISA with wells coated with purified mAbs. Except for parental anti-human CD19 mAb (FMC63) all other antibodies exhibited negligible cross reactivity to CD19scFv specific mAb ( Fig. 2A) . Anti-CD19scFv binds to its parental mAb at concentration as low as 2 mg/mL with binding saturated at 4 mg/mL. The specificity of this mAb towards clone FMC63 was confirmed as it did not cross react to another antihuman CD19 antibody (Invitrogen, clone MHCD 1900). Further, it did not bind to purified human IgG and CD20-specific mAb. The ability of mAb (clone no. 136.20.1) to detect CD19 + CAR protein was verified by western blot using whole protein lysates obtained from ex vivo-propagated CD19-specific CAR + T cells. MAb (clone no. 136.20.1) detected a ,75 kDa protein in CD19RCD28 modified cell lysates run in reducing SDS-PAGE and electroblotted onto PVDF membrane (Fig. 2B, lane B) . The specificity was verified on parallel by a commercial available CD3f antibody which detects CD3f signaling domain in CD19RCD28 expressing CAR (Fig. 2B, lane D) and endogenous CD3f in unmodified control T cells (Fig. 2B, lane A) . The ability of this mAb to detect the surface expression of CD19 + CAR was verified by flow cytometry analysis using CD19RCD28-expressing primary T cells and Jurkat cells (Fig. 3A) and (Fig. 3B) respectively. MAb (clone 136.20.1) detected expression of CD19scFv on surface of genetically modified T cells (85%) as well as in Jurkat cells (99%) which matches with detection level of anti-Fc antibodies that binds to CH 2 -CH 3 stalk of the CAR. Indeed, the staining pattern was compared with commercial IgG-c chain specific antibodies (Fc-PE Invitrogen) that binds to CH 2 -CH 3 region of the CAR and by mAb (clone no. 2D3 developed in-house) which binds to the CH 2 -CH 3 hinge region of the CAR (Fc-FITC) [13] . A panel of CAR + T cells that target different TAAs (CD33, CD123, ROR1, HERV-K) were used to verify if the clone no. 136.20.1 cross reacts with any of these CAR transgenes. Each CAR construct was expressed from Sleeping Beauty vector backbone and contains different signaling endodomains in addition to the common IgG 4 -derived hinge/ CH 2 -CH 3 linker. It did not cross react with any of other CARs tested other than those with specificity for CD19 (Fig. S2) . No background binding to mock-electroporated control T cells was observed. Additional evidence supporting specificity of mAb (clone no. 136.20.1) are provided as supplementary data (Fig. S3 and Fig.  S4 , kindly provided by Dr. Gianpietro Dotti at Baylor College of Medicine, Houston and Dr. Stephen Forman at City of Hope National Medical Center). In both cases CAR scaffold differs either by presence of human CD4 transmembrane region or IgG 1 Fc stalk that connects the scFv with the signaling endodomains. Furthermore, our mAb has been used to detect CD19-specific CAR + T cells that employ an extracellular domain derived from CD8a [5, 20] . These results demonstrate that irrespective of extracellular scaffolding and transmembrane domains, our mAb (clone no. 136.20.1) detects CD19scFv within CAR expressing scFv derived from FMC63.
The anti-CD19scFV mAb (clone no. 136.20.1) could be used in multi-parameter flow cytometry analysis to characterize CAR + cells selectively propagated on K562-derived aAPC [14, 16] . CARmodified T cells were numerically expanded in the presence of irradiated aAPC and cytokines (IL-2 and IL-21) for 4 weeks as previously reported [16] . The anti-CD19scFV mAb (clone 136.20.1) could detect both CD4
+ and CD8 + CAR + T cells (Fig. 3C) . We assessed the limit of detection using a spiking experiment. As shown in Fig. 4 , we were able to detect 1 CD19-specific CAR + T cell in 1,000 PBMC using anti-CD19scFV tagged to a AlexaFluor 647 dye. The assay was validated in PBMC obtained from two individual donors by an independent laboratory (Immune Monitoring Core lab) at MDACC (Representative data along with dilution schematic and gating strategy are provided in Fig. S5 . The anti-CD19scFV mAb could help in detecting the presence of CAR + T cells in patients after infusion (Fig. S4 demonstrating Fig. 5A shows anti-CD19scFv mAb when used at a concentration of 1:500 can establish surface localization of CARs in genetically modified T cells by immunocytochemistry. We have also established the utility of this mAb in immunohistochemistry using CAR + T cells fixed in neutral buffer formalin (Fig. S6) and we are currently working to detect CAR + T cells in bone marrow of patients infused with CD19-specific CAR + T cells. To detect CAR molecules on surface of genetically engineered T cells by electron microscopy, mAb (clone no. 136.20.1) was tagged to gold-labeled nanoparticles. Control unmodified T-cell sections are shown in plate (Fig. 5B i-iii) . The size of the conjugated nanogold (1.4 nm) precluded detection within thick sections of CAR + T cells (Fig. 5B plate iv) . Thus, we performed a silver enhancement process and could view CARs as detected by clone no. 136.20.1 conjugated nanoparticles within 100 nm thin sections ( Fig. 5B v and vi) . The silver enhancement was performed on non-stained samples as uranyl acetate staining prevented distin-guishing nanoparticles from other cellular granules. These studies establish the utility of clone no. 136.20.1 to detect CAR + T cells in fixed sections.
Anti-CD19scFv mAb can Block the Effector Function of CAR + T Cells
We evaluated functional properties of anti-CD19scFv mAb (clone no. 136.20.1) based on its ability to prevent lysis mediated by CD19-specific CAR + T cell. Previously we have developed and validated an approach for ex vivo expansion of genetically modified CAR + T cells on artificial antigen presenting cell (K562 clone no. 4). CAR + T cells receive proliferative signals from the TAA (CD19) coordinated with co-stimulatory molecules (CD86, CD137L, membrane bound IL15) cloned onto the surface of K562 cells [13, 14, 16] . The CD19-specific CAR + T cells used in this study were propagated on same K562-derived aAPC as published previously. A standard 4 hour CRA was performed using mouse T-cell lines EL4 (parental) and CD19 + EL4 as the tumor target. The percentage specific lysis was calculated using CD19-specific CAR + T cells bound to CD19scFv mAb or CD19-specific CAR + T cells alone. Fig. 6A shows that anti-CD19ScFv mAb completely inhibits CAR-dependent killing (at 250 mg/mL) by blocking the ability of CAR to dock to the TAA. However, at 25 mg/mL the anti-Id inhibited killing at 30% maximum and there was little or no effect when the mAb concentration was reduced to 5 mg/mL (Fig. 6B) . We repeated the experiment in two other B-cell lines (Daudib 2 m and NALM-6) to validate that inhibition of lysis could be achieved in alternate B-cell tumors. The application of anti-CD19scFv at 250 mg/mL reduced the cytolytic activity to 18% in Daudib 2 m and 32% in NALM-6 (Fig. S7) . We hypothesize that the mechanism of lysis may not be same in all these tumor cell lines and hence the degree of inhibition differed. To investigate the inhibitory effect of anti-CD19scFv mAb in real time, we used VTLM to serially monitor the killing process in a coculture experiment involving Daudib 2 m as tumor target and CD19-specific CAR + T cells as effectors. As control, we used a Fcspecific F(ab9) 2 fragment of an antibody that bound to the scaffolding of CD19RCD28. CAR + T cells continued lyse tumor cells when the effector cells were bound by this control antibody (Fig. 6 i-iii; Movie S1). In contrast, CAR + T cells were unable to kill target cells when bound by anti-CD19scFv mAb (Fig. 6 iv-vi; Movie S2). We reasoned that blocking by clone no. 136.20.1 prevented triggering of T cells which supports our claim that this mAb binds within the scFv domain of the CAR.
Discussion
We developed and validated a mAb that recognizes scFv region of a CD19-specific CAR derived from anti-human CD19 mAb FMC63. Previously, CARs expressed on the T-cell surface were detected by antibodies directed against epitope tags or spacer domains incorporated in the extracellular domain. For example, the CAR recognizing prostate specific membrane antigen (PSMA) and erbB2 were detected by V5-specific or myc-specific mAbs [21, 22] . Spacer or scaffolding domains appending the scFv within the CAR from the cell surface can be derived from the hinge/ CH 2 -CH 3 domain of IgG 1 [23] or IgG 4 (Fig. 1A) . Commerciallyavailable antibodies detecting Fc regions can detect these CARs [1, 24, 25] but there is the potential for cross-reactivity against immunoglobulin especially when genetically modified T cells are to be assayed from patient-derived PBMC. Alternative CAR designs that are non-immunogenic [26] , avoid using a CH 2 -CH 3 domain for concern of binding to IgG Fc gamma receptors [27] , and employ scaffolding domains that are smaller than the Fc region, may improve the therapeutic potential of genetically modified T cells. Thus, reagents such as mAb clone no. 136.20.1 that can directly detect the scFv region of the CAR may have increasing utility. Indeed, the anti-idiotype mAb we developed for detection of CD19-specific CAR + T cells provides a methodology to generate reagents to detect CARs targeting TAAs alternative to CD19.
The application of our anti-CD19scFv mAb to enhance correlative studies has been demonstrated in studies following the fate of infused CAR + T cells (ClinicalTrials.gov number Most CARs developed to redirect T-cell specificity to TAAs employ scFvs derived from mouse mAbs [28] . Anti-idiotypic mAbs that bind CARs have been previously reported, for example antiLeu Y or anti-GD2 [29, 30] . The idiotype specific mAb reported here has utility beyond detecting the CAR on T cells as monitoring host immune response targeting the scFv is needed to inform on the potential for immune-mediated clearance of the infused CAR + T cells. Hence, it may be necessary to determine if a recipient's immune response is directed against the scFv region and thus can interfere with binding of the CAR + T cells to the TAA. In a recent study, adoptively transferred antigen specific CAR + T cells were shown to induce humoral response as detected by circulating anti-Id antibodies (up to 1 mg/mL) in infused patients [26] . Significantly, an anti-idiotypic response was found to neutralize CAR binding carbonic anhydrase IX (CAIX) that compromised the clinical utility of this immunotherapy. In this context, we determined that mAb clone no. 136.20.1 could inhibit the effector function of CD19-specific CAR + T cells. In the clinical setting, the antiidiotype antibody response that interfered with CAR + T cells occurred at mAb concentrations lower than we used to block lysis in CRA and VTLM. This could be due to different dynamics in an in vitro assay system where the CAR + T cells act rapidly on tumor targets expressing high loads of antigen. An ability to block the + cells. [7] . In summary, we report an anti-idiotype mAb that binds to the scFv derived from anti-human CD19 mAb FMC63 which can detect genetically modified CD19-specific T cells and interferes with killing of CD19 + target cells. This reagent will be helpful to multiple investigators involved in developing and implementing gene therapy trials infusing CAR + T cells. 
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